SCHEMBL19985073

SCHEMBL19985073

Cc1ccccc1[C@H](C)CCCl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.43
TSHR P16473 2/20 0.36
ACHE P22303 1/20 0.36
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 1/20 0.36
CYP19A1 P11511 1/20 0.36
NR3C2 P08235 1/20 0.35
ACP3 P15309 1/20 0.34
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
CYP2D6 P10635 2/20 0.33
SLC6A3 Q01959 2/20 0.33
SLC22A2 O15244 1/20 0.33
SLC22A1 O15245 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22416799 1.00 ESR1 (0.43) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL7176631 0.87 ESR1 (0.50) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL9227464 0.86 ESR1 (0.39) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL11800593 0.81 ESR1 (0.45) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL17755167 0.79 ESR1 (0.43) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL10699377 0.79 TRPA1 (0.44) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL19847785 0.78 ESR1 (0.42) ESR1TSHRACHEADRA2AADRA2B
SCHEMBL20228717 0.78 CYP3A4 (0.38) TSHRACHESLC6A2SLC6A4CYP3A4
SCHEMBL3918911 0.78 ESR1 (0.42) ESR1TSHRACHECYP19A1ACP3
SCHEMBL3918915 0.78 ESR1 (0.42) ESR1TSHRACHECYP19A1ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3279188-B1 AXIALLY CHIRAL ISOMERS, AND PREPARATION METHODS THEREFOR AND PHARMACEUTICAL USES THEREOF MEDSHINE DISCOVERY INC (CN) 2020-09-09 EP disclosed
US-10183915-B2 Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof MEDSHINE DISCOVERY INC. (CN) 2019-01-22 US disclosed
US-20180079731-A1 AXIALLY CHIRAL ISOMERS, AND PREPARATION METHODS THEREFOR AND PHARMACEUTICAL USES THEREOF MEDSHINE DISCOVERY INC. (CN) 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079731-A1 AXIALLY CHIRAL ISOMERS, AND PREPARATION METHODS THEREFOR AND PHARMACEUTICAL USES THEREOF CYP4F11, CYP4A11, SLC39A11 ESR1 3125/4885TSHR 3847/4885ACHE 2128/4885
US-10183915-B2 Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof CYP4F11, CYP4A11, SLC39A11 ESR1 3125/4885TSHR 3847/4885ACHE 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.